TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for TherapeuticsMD.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for TherapeuticsMD.

Recommendation Trends

Rating	Mar '23	Apr '23	May '23	Jun '23	Jul '23	Aug '23
Strong Buy	0	0	0	0	0	0
Buy	0	0	0	0	0	0
Hold	2	2	2	2	2	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $5	Hold	Reiterates	$5	+401.91%	Aug 17, 2023
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Hold Initiates $5	Hold	Initiates	$5	+401.91%	Jan 11, 2023
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $1	Hold	Reiterates	$1	+0.38%	Jul 13, 2022
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades $10	Strong Buy → Hold	Downgrades	$10	+903.81%	Jun 7, 2022
Louise Chen Cantor Fitzgerald	Cantor Fitzgerald	Buy → Hold Downgrades $250 → $50	Buy → Hold	Downgrades	$250 → $50	+4,919.07%	May 6, 2022

More Analyst Ratings

Financial Forecast

Revenue This Year

9.28M

Increased by 427.09%

from 1.76M

Revenue Next Year

n/a

from 9.28M

EPS This Year

0.36

from -0.19

EPS Next Year

n/a

from 0.36

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	64.87M	2.57M	69.96M	1.30M	1.76M	9.28M
Revenue Growth	30.67%	-96.03%	2,619.12%	-98.14%	35.25%	427.09%
EPS	-33.50	-21.66	11.95	-0.99	-0.19	0.36
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	2.79
No. Analysts	-	-	-	-	-	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025
High	9.6M
Avg	9.3M
Low	8.9M

Revenue Growth

Revenue Growth	2025
High	442.6%
Avg	427.1%
Low	406.4%

EPS Forecast

EPS	2025
High	0.37
Avg	0.36
Low	0.34

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.